Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Crown Laboratories Extension Of Tender Offer To Acquire Revance Therapeutics, Inc. At A Price Of $3.10 Per Share In Cash

Author: Benzinga Newsdesk | January 13, 2025 09:03am

Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced that, at the request of Revance Therapeutics, Inc., ("Revance") (NASDAQ:RVNC), it has extended the expiration of its cash tender offer to acquire all of the issued and outstanding shares of common stock, par value $0.001 per share ("Shares") of Revance, at a price of $3.10 per Share in cash, without interest and less any applicable tax withholding.

Posted In: RVNC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist